Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Income from Continuing Operations (2016 - 2025)

China Pharma Holdings filings provide 16 years of Income from Continuing Operations readings, the most recent being 1222135.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations changed 0.19% to 1222135.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 3187556.0, a 32.7% increase, with the full-year FY2025 number at 3187556.0, up 32.7% from a year prior.
  • Income from Continuing Operations hit 1222135.0 in Q4 2025 for China Pharma Holdings, down from 651482.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 475976.0 in Q1 2023 to a low of 1438130.0 in Q2 2024.
  • Median Income from Continuing Operations over the past 5 years was 857531.5 (2021), compared with a mean of 918752.8.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 6418.56% in 2021 and later soared 63.26% in 2025.
  • China Pharma Holdings' Income from Continuing Operations stood at 980719.0 in 2021, then dropped by 28.9% to 1264184.0 in 2022, then increased by 2.53% to 1232213.0 in 2023, then grew by 0.63% to 1224432.0 in 2024, then rose by 0.19% to 1222135.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 1222135.0 (Q4 2025), 651482.0 (Q3 2025), and 528367.0 (Q2 2025) per Business Quant data.